Evidence map›Paper›PMID 29592796›Full record

ArticleBMC nephrology2018

C3 glomerulopathy in cystic fibrosis: a case report.

Domenico Santoro, Rossella Siligato, Carmela Vadalà, Mariacristina Lucanto, Simona Cristadoro, Giovanni Conti, Michele Buemi, Stefano Costa, Ettore Sabadini, Giuseppe Magazzù

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Domenico SantoroDepartment of Clinical and Experimental Medicine, University of Messina, Via Faranda, 2-98123, Messina, Italy. dsantoro@unime.it.ORCID 0000-0002-4279-6559
Rossella SiligatoDepartment of Clinical and Experimental Medicine, University of Messina, Via Faranda, 2-98123, Messina, Italy.
Carmela VadalàDepartment of Clinical and Experimental Medicine, University of Messina, Via Faranda, 2-98123, Messina, Italy.
Mariacristina LucantoUnit of Pediatric Gastroenterology and Cystic Fibrosis, University of Messina, Messina, Italy.
Simona CristadoroUnit of Pediatric Gastroenterology and Cystic Fibrosis, University of Messina, Messina, Italy.
Giovanni ContiUnit of Pediatric Nephrology and Rheumatology, University of Messina, Messina, Italy.
Michele BuemiDepartment of Clinical and Experimental Medicine, University of Messina, Via Faranda, 2-98123, Messina, Italy.
Stefano CostaUnit of Pediatric Gastroenterology and Cystic Fibrosis, University of Messina, Messina, Italy.
Ettore SabadiniUnit of Nephrology, Hospital Riuniti, Bergamo, Italy.
Giuseppe MagazzùUnit of Pediatric Gastroenterology and Cystic Fibrosis, University of Messina, Messina, Italy.
University of Messina · ITAzienda Ospedaliero Universitaria Ospedali Riuniti · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundC3 glomerulonephritis is a rare glomerulopathy characterized at renal biopsy by C3 deposition, alone or with scanty immunoglobulins, as well as by an electron-dense material in mesangium, subendothelial and subepithelial space. An abnormal systemic activation of the alternative pathway of the complement cascade is responsible for the development of the disease if triggered by several possible environmental conditions. We report the first case in literature of a patient affected by cystic fibrosis and C3GN. CASE PRESENTATION: Our case involves a young woman with cystic fibrosis, who had persistent microscopic hematuria, proteinuria and hypocomplementemia C3 for over three months. Renal biopsy confirmed the diagnosis of C3 glomerulopathy. Complement system dysregulation was tested and resulted in a strong terminal pathway activation proved by high levels of sC5b-9 complex, amounting to 1588 ng/ml (normal value < 400 ng/ml). Next generation sequencing (NGS) showed polymorphism in CFH (p.V62I in SCR1) and THBD (p.A473V), already known as pathogenic for C3GN, as well as a mutation in C3 (p.R102G) associated only with age-related macular degeneration (AMD) so far. Treatment was based on ACE inhibitors and kidney function is currently stable (GFR 50 ml/min, serum creatinine 1.7).

conclusionsThe co-existence of C3 glomerulopathy in a patient with CF, which is characterized by chronic infection/inflammation, makes this case an interesting model of chronic altered systemic activation of the alternative pathway of the complement cascade.

Indexed as

AdultComplement C3Cystic FibrosisFemaleGlomerulonephritisHumansComplement C3C3 glomerulopathyCystic fibrosisInflammationRenal biopsy

Identifiers

PMID29592796
PMCPMC5875003
OpenAlexW2795109866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.